Immunoprotein Diagnostic Testing Market Analysis

  • Report ID: 5311
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Immunoprotein Diagnostic Testing Market Analysis

Technology (Chemiluminescence Assay, Enzyme-based Immunoassay, Immunofluorescence Assay, Immunoturbidity Assay, Immunoprotein Electrophoresis)

Immunoprotein diagnostic testing market from the chemiluminescence essay segment is set to hold the largest revenue share of 30% by the end of 2037. The growth may be attributable to a high degree of specificity and sensitivity as well as the ability to identify antigens in human serum or plasma samples. The Chemiluminescence assay is often regarded as an important tool for the rapid identification of a particular disease and it has been shown to be more precise than fluorescently detecting probes, which are labeled.  Furthermore, the enzyme-based immunoassay is estimated to offer lucrative growth opportunities for the market in the upcoming time period. In a large number of companies and laboratories, it can also be used to diagnose disease, as well as for quality control. In addition, a large number of EIA analyzers are at the disposal of most major companies. For example, this technology is used for diagnostic purposes in the Human Complement C3 ELISA Kit by Abcam.

Application (Infectious Disease, Endocrine, Toxicology)

The endocrine segment in the immunoprotein diagnostic testing market is estimated to hold a substantial revenue share during the forecast period. The growing burden of endocrine diseases, such as diabetes, and the development of products related to immunodiagnostic testing are driving the growth of this segment. According to 2022 statistics, in the United States, type 1 diabetes increased by 2.9% per year, compared to 4.5% for type 2 diabetes. Similarly, according to the US CDC, in 2022, 96 million adults have prediabetes in the U.S., and 8 out of 10 of them don't know if they have the condition. More than 37 million people are living with diabetes and one in five are undiagnosed. Therefore, the significant increase in the prevalence of diabetes is increasing the demand for immunoprotein testing diagnostics, which will have a positive impact on the market.

Our in-depth analysis of the global market includes the following segments:

          Product Type

  • Instruments
  • Kits & Reagents

          Technology

  • Chemiluminescence Assay
  • Enzyme-based Immunoassay
  •  Immunofluorescence Assay
  • Immunoturbidity Assay
  • Immunoprotein Electrophoresis

          Application

  • Infectious Disease
  • Endocrine
  • Toxicology
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5311
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of immunoprotein diagnostic testing is estimated at USD 9.94 billion.

The immunoprotein diagnostic testing market size was over USD 9.38 billion in 2024 and is set to cross USD 24.02 billion by the end of 2037, witnessing more than 7.5% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of chronic disease and rise in diagnostic tests will boost the market growth.

Asia Pacific industry is expected to dominate majority revenue share 35% by 2037, due to rising development of medical health systems in the region.

The major players in the market are of Bio-Rad Laboratories, Inc, Danaher Corporation, DiaSorin S.p.A, Enzo Biochem, Ortho Clinical Diagnostics, KSL Diagnostics Inc., KSL Beutner Laboratories, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample